Alyeska Investment Group
HZNP

Alyeska Investment Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Alyeska Investment Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-850,000
Closed -$12.9M – 483
2014
Q1 		$12.9M Hold
850,000
– – 0.35% 111
2013
Q4 		$6.48M Hold
850,000
– – 0.26% 141
2013
Q3 		$2.85M Hold
850,000
– – 0.12% 195
2013
Q2 		$2.09M Buy
+850,000
New +$2.04M 0.1% 194

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alyeska Investment Group's HZNP Position: Q1 2023 in Review

Alyeska Investment Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 3,113 shares — an estimated $354K sold.

Alyeska Investment Group first reported a position in HZNP in Q2 2013 and held it in 16 quarters. The position peaked at $58.2M in Q4 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Alyeska Investment Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 3,113 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $354K.
  • Alyeska Investment Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 16 quarters.
  • Alyeska Investment Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $58.2M in Q4 2021.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Alyeska Investment Group's 13F filing for Q1 2023, filed 15 May 2023.